Business Wire

Jeffrey Lawrence Appointed Chairman of Joe & the Juice

24.4.2025 10:00:00 EEST | Business Wire | Press release

Share

Joe & the Juice (“the Company”), an urban juice bar and coffee concept selling freshly prepared juices, coffee, sandwiches and more, today announced that Jeffrey Lawrence, a member of the Company’s Board of Directors since April 2024, has been appointed as Chairman of the Board.

Thomas Nørøxe, Chief Executive Officer of Joe & the Juice, said, “Jeff’s elevation to Chairman of Joe & the Juice reflects how his active participation has made a material difference to the Company’s performance and strategy. Over the past year, Joe & the Juice has achieved continued impressive same store sales and revenue growth as we also opened our 400th unit globally. Unit economics remain incredibly strong and digital sales are now nearing 40%. Jeff’s experience will be vital as we continue to expand globally through both company-owned and franchise openings.”

Jeffrey Lawrence commented, “Joe & the Juice continues to represent one of the most exciting and dynamic restaurant brands, with true global consumer appeal. Over time, the Company has finetuned a winning formula to provide fresh, quality products, with a focus on hospitality and meeting the needs of today’s digitally-enabled consumer. I have been inspired by the ambition and potential of the team and look forward to working closely together to continue to build the Joe & the Juice brand globally.”

Mr. Lawrence holds more than 25 years of leadership experience in building digitally-enabled foodservice and consumer brands. He spent more than two decades at Domino’s Pizza (NYSE: DPZ), including five years as Executive Vice President and Chief Financial Officer, playing a critical role in the company’s successful IPO, its significant international expansion and best in class increases in store-level profitability. Mr. Lawrence was also an integral part of the global pizza chain’s transformation through the adoption and optimization of digital and data-led initiatives.

After his time at Domino’s, Mr. Lawrence served as CFO of FIGS, Inc. (NYSE: FIGS), a direct-to-consumer apparel brand, where he led the company’s 2021 IPO, and then as CFO at ShiftKey.

He currently serves as an independent board member and Chairman of the Audit Committee at Shake Shack (NYSE: SHAK) and an independent board member at Xponential Fitness (NYSE: XPOF), as well as a Senior Advisor to General Atlantic, a leading global growth investor.

Joe & the Juice currently operates in more than 400 locations across 19 countries spanning the UK and Europe, United States, Middle East and Asia. Capitalizing on strong customer demand, the Company’s enhanced digital distribution channels and strong franchising partnerships have enabled it to rapidly expand its regional presence in key markets.

About Joe & the Juice

Joe & the Juice is an urban juice bar and coffee concept operating in more than 400 locations across 19 countries. Founded in 2002, the company sells freshly prepared juices, coffee, sandwiches and more. Joe & the Juice’s differentiated concept creates a modern, urban, and hip ambiance for on-the-go customers focused on a healthy lifestyle. For more on our authentic and unique brand: www.joejuice.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250424086704/en/

Contacts

Media Contacts
Joe & the Juice
Kasper Garnell
garnell@joejuice.com
+45 2019 5904

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye